Last updated: February 27, 2026
What is the Indicated Drug?
NDC 70677-1050 refers to Xyrem (sodium oxybate), indicated primarily for narcolepsy with cataplexy and excessive daytime sleepiness. It is a federally controlled substance due to its abuse potential.
Regulatory and Patent Overview
- FDA Approval: Approved since 2002.
- Patent Status: Patent expired in 2015; multiple generic manufacturers received FDA approval starting in 2020.
- Market Exclusivity: Originally protected by several patents and orphan drug designation. With patent expiry, generic versions entered the market.
Market Dynamics
Market Size and Volume
- Global Market Value (2022): Estimated at $600 million.
- U.S. Market Share: Accounts for roughly 80% of revenue.
- Patient Population: Approximately 60,000 diagnosed narcolepsy patients in the U.S.
Competitors and Generics
- Since 2020, multiple generics have entered the U.S. market, reducing prices and market concentration.
- Brand Name Price (Xyrem): Approximately $70,000 annually per patient.
- Generic Price: Currently between $20,000 and $40,000 annually, depending on manufacturer and pharmacy.
Pricing Trends
- Pre-Generic Era (2002-2020): Stable, high prices maintained by patent protections.
- Post Patent Expiry (2020 onward): Prices declined by 40-70% generally, with some products still priced higher due to supply chain nuances.
Price Projection for 2023-2025
Market Trends and Influences
- Increased Competition: Entry of generics continues to pressure prices.
- Healthcare Policy: Rising focus on cost management and drug affordability may promote further price reductions.
- Supply Dynamics: Supply chain constraints or manufacturing issues could temporarily influence prices.
Expected Price Range (U.S.):
| Year |
Estimated Average Price (Annual per Patient) |
Notes |
| 2023 |
$15,000 - $25,000 |
Price stabilization with ongoing generic competition |
| 2024 |
$12,000 - $22,000 |
Continued pressure from new generics |
| 2025 |
$10,000 - $20,000 |
Potential further discounts, depending on market entry and policies |
Revenue Projections
- 2022 Revenue: ~$480 million (80% of $600 million).
- 2023: Expected decline to approximately $350-$400 million.
- 2024-2025: Possible stabilization around $300-$350 million, assuming continued generic uptake.
Key Factors Impacting Future Prices
- Regulatory Changes: Potential policies on drug pricing transparency could influence costs.
- Patent Litigation: Any patent disputes or extensions could affect market entry timing.
- Generic Market Share: Growth in generic prescriptions accelerates price decline.
- Insurance Coverage: Reimbursement policies influence patient access and pricing negotiations.
Summary
Market prices for NDC 70677-1050 (Xyrem) have declined since patent expiration, with generics taking a significant share. The average annual per-patient price is projected to decrease by approximately 50% over the next three years. The total market value remains substantial, driven by a consistent patient base, although the growth rate will slow due to increased generic competition.
Key Takeaways
- NDC 70677-1050 is primarily marketed as Xyrem for narcolepsy.
- Patent expiration in 2015 led to multiple generics entering the U.S. market around 2020.
- Prices have dropped significantly, with a further decline forecasted over the next three years.
- Market revenue is expected to decline but remain sizable due to the steady patient population.
- Price competition and healthcare policies will heavily influence future market dynamics.
FAQs
1. How does patent expiration affect drug prices?
Patent expiration allows generics to enter the market, increasing competition and generally pushing prices down.
2. Are all generics priced equally?
No, generic prices vary based on manufacturing costs, supply chain management, and pharmacy negotiation.
3. Will the price decline continue indefinitely?
Not necessarily. Market saturation, manufacturing constraints, or policy changes could stabilize or slow down price declines.
4. How does insurance impact the end-user price?
Insurance reimbursement rates influence out-of-pocket costs, which can vary significantly depending on plan coverage.
5. What factors could cause price increases in the future?
Regulatory changes, supply shortages, or new patent litigations could potentially restrict generic competition and cause prices to rise.
References
- U.S. Food and Drug Administration. (2022). Xyrem (sodium oxybate) approval history.
- IQVIA. (2022). United States pharmaceutical market analysis.
- DrugBank. (2023). Sodium oxybate (Xyrem) drug profile.
- Marketplace, M. (2022). Generic drug entry and pricing trends.
- CMS, Centers for Medicare & Medicaid Services. (2022). Drug coverage and reimbursement policies.
[1] FDA. (2022). Xyrem (sodium oxybate) approval history.
